Icecure Medical Ltd Ord (ICCM)

$1.13 -0.02 (-1.32%)
Market Cap 62.44M
Revenue (ttm) 3.29M
Net Income (ttm) -15.32M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -465.65%
Debt to Equity Ratio 0.00
Volume 62,700
Avg Vol 329,734
Day's Range N/A - N/A
Shares Out 55.50M
Stochastic %K 47%
Beta 0.43
Analysts Strong Sell
Price Target $3.13

Latest News on ICCM

IceCure Medical Ltd (ICCM) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 1:45 PM EDT - 23 days ago

IceCure Medical Ltd (ICCM) Q4 2024 Earnings Call Transcript

IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America

Mar 27, 2025, 8:30 AM EDT - 23 days ago

IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America

IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate

Mar 24, 2025, 8:30 AM EDT - 26 days ago

IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate

IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025

Mar 21, 2025, 8:30 AM EDT - 4 weeks ago

IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025

IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer

Mar 20, 2025, 8:30 AM EDT - 4 weeks ago

IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer

IceCure's ProSense® Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference

Mar 18, 2025, 8:30 AM EDT - 4 weeks ago

IceCure's ProSense® Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference

IceCure Receives Notice of Allowance in China for Novel Cryogenic Pump for Next-Generation Cryoablation Technology

Mar 17, 2025, 8:30 AM EDT - 4 weeks ago

IceCure Receives Notice of Allowance in China for Novel Cryogenic Pump for Next-Generation Cryoablation Technology

Breast Cancer Patients who Underwent IceCure's ProSense® Cryoablation in Japan Reported Significantly Higher Satisfaction than Patients who Underwent Standard of Care Surgery

Mar 10, 2025, 8:30 AM EDT - 5 weeks ago

Breast Cancer Patients who Underwent IceCure's ProSense® Cryoablation in Japan Reported Significantly Higher Satisfaction than Patients who Underwent Standard of Care Surgery

IceCure Submits Filing for Regulatory Approval of its Next-Generation XSense™ Cryoablation System in Israel

Feb 24, 2025, 8:30 AM EST - 7 weeks ago

IceCure Submits Filing for Regulatory Approval of its Next-Generation XSense™ Cryoablation System in Israel

IceCure's ProSense® in the Spotlight at Society of Interventional Oncology (SIO) Annual Meeting: Award Winning Abstract and Hands-On Training for Breast Cryoablation as Medical Community Anticipates FDA's Market Authorization Decision

Feb 4, 2025, 8:30 AM EST - 2 months ago

IceCure's ProSense® in the Spotlight at Society of Interventional Oncology (SIO) Annual Meeting: Award Winning Abstract and Hands-On Training for Breast Cryoablation as Medical Community Anticipates FDA's Market Authorization Decision

IceCure Files for Regulatory Approval of ProSense® Cryoablation System in China

Jan 27, 2025, 8:30 AM EST - 2 months ago

IceCure Files for Regulatory Approval of ProSense® Cryoablation System in China

IceCure Medical CEO Issues Letter to Shareholders & Reports Increase of 42% in ProSense® Sales for 2024 in North America

Jan 13, 2025, 7:00 AM EST - 3 months ago

IceCure Medical CEO Issues Letter to Shareholders & Reports Increase of 42% in ProSense® Sales for 2024 in North America

IceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minimum Closing Bid Price Rule

Jan 6, 2025, 8:30 AM EST - 3 months ago

IceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minimum Closing Bid Price Rule

European Patent Office Issues Intention to Grant Notice to IceCure for its Next-Generation Cryoablation Technology

Jan 3, 2025, 8:30 AM EST - 3 months ago

European Patent Office Issues Intention to Grant Notice to IceCure for its Next-Generation Cryoablation Technology

Data on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting

Dec 16, 2024, 8:30 AM EST - 4 months ago

Data on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting

IceCure Medical Ltd (ICCM) Q3 2024 Earnings Call Transcript

Nov 26, 2024, 1:46 PM EST - 5 months ago

IceCure Medical Ltd (ICCM) Q3 2024 Earnings Call Transcript

IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation

Nov 26, 2024, 8:30 AM EST - 5 months ago

IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation

IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent Office

Nov 25, 2024, 8:30 AM EST - 5 months ago

IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent Office

IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024

Nov 20, 2024, 8:30 AM EST - 5 months ago

IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024

IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health

Nov 19, 2024, 8:30 AM EST - 5 months ago

IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health

FDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer

Nov 8, 2024, 7:00 AM EST - 5 months ago

FDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer

Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders

Oct 29, 2024, 8:30 AM EDT - 6 months ago

Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders

IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation System

Oct 21, 2024, 8:30 AM EDT - 6 months ago

IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation System

IceCure's ProSense® Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging Conference

Oct 7, 2024, 8:15 AM EDT - 6 months ago

IceCure's ProSense® Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging Conference

IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate

Sep 24, 2024, 8:15 AM EDT - 7 months ago

IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate

Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues

Sep 16, 2024, 8:00 AM EDT - 7 months ago

Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues

IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024

Sep 12, 2024, 8:00 AM EDT - 7 months ago

IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024

IceCure to Meet Institutional Investors at the H.C. Wainwright and Lake Street Capital Markets Conferences

Sep 4, 2024, 8:30 AM EDT - 8 months ago

IceCure to Meet Institutional Investors at the H.C. Wainwright and Lake Street Capital Markets Conferences

USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation Technologies

Aug 28, 2024, 8:30 AM EDT - 8 months ago

USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation Technologies

IceCure Medical Ltd (ICCM) Q2 2024 Earnings Call Transcript

Aug 20, 2024, 3:29 PM EDT - 8 months ago

IceCure Medical Ltd (ICCM) Q2 2024 Earnings Call Transcript

IceCure Medical Reports 20% Growth in ProSense® System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global Markets

Aug 20, 2024, 8:30 AM EDT - 8 months ago

IceCure Medical Reports 20% Growth in ProSense® System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global Markets

IceCure's ProSense® Destroyed 100% of Breast Cancer Tumors in Independent Study of Patients Who Chose Cryoablation Instead of Surgery

Aug 14, 2024, 8:30 AM EDT - 8 months ago

IceCure's ProSense® Destroyed 100% of Breast Cancer Tumors in Independent Study of Patients Who Chose Cryoablation Instead of Surgery

IceCure Medical to Report Second Quarter 2024 Financial & Operational Results on August 20, 2024

Aug 13, 2024, 8:30 AM EDT - 8 months ago

IceCure Medical to Report Second Quarter 2024 Financial & Operational Results on August 20, 2024

IceCure Announces Positive Data from the Largest Multi-Institutional Study of its Kind: "Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials"

Aug 7, 2024, 8:30 AM EDT - 9 months ago

IceCure Announces Positive Data from the Largest Multi-Institutional Study of its Kind: "Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials"

99.74% Recurrence Free Rate for Women with Breast Cancer Treated with IceCure's ProSense® Cryoablation System: Key Findings Delivered at 32nd Annual Meeting of the Japanese Breast Cancer Society

Jul 22, 2024, 8:30 AM EDT - 9 months ago

99.74% Recurrence Free Rate for Women with Breast Cancer Treated with IceCure's ProSense® Cryoablation System: Key Findings Delivered at 32nd Annual Meeting of the Japanese Breast Cancer Society

IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification

Jul 19, 2024, 4:30 PM EDT - 9 months ago

IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification

European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer

Jul 9, 2024, 8:30 AM EDT - 10 months ago

European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer

U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation System with CryoProbes

Jul 1, 2024, 8:30 AM EDT - 10 months ago

U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation System with CryoProbes

IceCure Medical to Provide Overview and Share Recent Progress at Northland Capital Markets Virtual Growth Conference on June 25, 2024

Jun 18, 2024, 8:30 AM EDT - 10 months ago

IceCure Medical to Provide Overview and Share Recent Progress at Northland Capital Markets Virtual Growth Conference on June 25, 2024

Positive Data from IceCure's Kidney Cancer Clinical Study Presented at Interventional Radiology Conference: Minimally Invasive Approach Results in Shorter Hospitalization and Minor Impact on Renal Function

Jun 12, 2024, 8:30 AM EDT - 11 months ago

Positive Data from IceCure's Kidney Cancer Clinical Study Presented at Interventional Radiology Conference: Minimally Invasive Approach Results in Shorter Hospitalization and Minor Impact on Renal Function

FDA to Convene Advisory Panel for Review of IceCure's De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025; Aligns with Commercial Readiness Plan

Jun 4, 2024, 8:30 AM EDT - 11 months ago

FDA to Convene Advisory Panel for Review of IceCure's De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025; Aligns with Commercial Readiness Plan

IceCure Medical Ltd (ICCM) Q1 2024 Earnings Call Transcript

May 28, 2024, 5:06 PM EDT - 11 months ago

IceCure Medical Ltd (ICCM) Q1 2024 Earnings Call Transcript

IceCure Medical Maintains Positive Momentum and Reports Sales Growth for Cryoablation System in First Quarter of 2024

May 28, 2024, 8:30 AM EDT - 11 months ago

IceCure Medical Maintains Positive Momentum and Reports Sales Growth for Cryoablation System in First Quarter of 2024

IceCure Medical to Report First Quarter 2024 Financial & Operational Results on May 28, 2024

May 21, 2024, 8:53 AM EDT - 11 months ago

IceCure Medical to Report First Quarter 2024 Financial & Operational Results on May 28, 2024

IceCure Medical to Highlight Key Achievements and Provide Business Overview at A.G.P. / Alliance Global Partners' Virtual Healthcare Company Showcase

May 20, 2024, 8:30 AM EDT - 11 months ago

IceCure Medical to Highlight Key Achievements and Provide Business Overview at A.G.P. / Alliance Global Partners' Virtual Healthcare Company Showcase

Independent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense®, Adding to Continued Positive Data Published Globally

May 7, 2024, 8:30 AM EDT - 1 year ago

Independent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense®, Adding to Continued Positive Data Published Globally

IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer

Apr 15, 2024, 8:35 AM EDT - 1 year ago

IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer

IceCure Medical Ltd. (ICCM) Q4 2023 Earnings Call Transcript

Apr 3, 2024, 1:20 PM EDT - 1 year ago

IceCure Medical Ltd. (ICCM) Q4 2023 Earnings Call Transcript

IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance

Apr 3, 2024, 8:30 AM EDT - 1 year ago

IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance

IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes

Apr 2, 2024, 8:30 AM EDT - 1 year ago

IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes